BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling ...

New data analysis on Tirbanibulin shows consistent treatment response for actinic keratosis (AK): data from phase IV and real-world evidence studies show consistently high levels of response as well ...